MGI Pharma - Best Pharma Stocks of 2007

Company: MGI Pharma
Starting stock price: $18.11
Ending stock price: $40.53
Percent Change: 123.8%

Details: MGI markets Aloxi for prevention of chemotherapy-induced nausea and vomiting, Dacogen for myelodysplastic syndromes, and Gliadel Wafers for high grade malignant gliomas as an adjunct to surgery and radiation. In December 2007, MGI Pharma announced that Japan's Eisai had agreed to buy the company for $3.9 billion, a 23 percent premium over the December 7 close. MGI has 10 development programs underway for everything from preclinical therapeutics to late-stage studies on approved medications.

More News:
Eisai expands U.S. ops with $3.9B MGI buyout. Report
Lehman helps MGI study its 'strategic alternatives'. Report
MGI lands $255M buyout option in drug deal. Report
MGI therapy "approvable," but FDA wants new trial. Report
MGI sets sights on late-stage Aquavan trials. Report

MGI Pharma - Best Pharma Stocks of 2007
Read more on

Suggested Articles

Bluebird Bio has overcome a manufacturing hiccup that looked like it would delay its gene therapy launch in Europe until next year.

Lilly's top U.S. executive is on his way out. Enrique Conterno, who also heads up Lilly's global diabetes business, will step down at year's end.

GlaxoSmithKline, Pfizer, Sanofi and Boehringer Ingelheim are facing lawsuit claims that they failed to test for possible carcinogens in Zantac.